SHIM
NRIX icon

Stone House Investment Management’s Nurix Therapeutics NRIX Stock Holding History

Stone House Investment Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97 Buy
+4
New +$68 ﹤0.01% 1289

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stone House Investment Management's NRIX Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 4 shares worth $97. The stake represents ﹤0.01% of the portfolio and ranks #1289 among its holdings.

211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Stone House Investment Management held 4 shares of Nurix Therapeutics worth $97 as of Q2 2026.
  • Nurix Therapeutics was a new Stone House Investment Management position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1289 holding.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.